CD8A and neoplasm: Overall, the combination of R848 and low‐dose sorafenib promoted increased macrophage–neutrophil interactions with DCs to induce the presentation of antigens to T cells, resulting in a CD8+ T cell‐mediated adaptive immune response against the tumor.